Activated α2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-β in the presence of interleukin-2

Journal of Immunotherapy

Volumn 21, Issue 2, 1998, Pages 85-94

  Harthun, Nancy L ^a   Weaver, Alissa M ^a   Brinckerhoff, Laurence H ^a   Deacon, Donna H ^a   Gonias, Steven L ^a   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cytotoxic T lymphocytes; Immunotherapy; Natural killer cells; Transforming growth factor ; 2 macroglobulin

Indexed keywords

ALPHA 2 MACROGLOBULIN; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN K 562; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0031890889     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199803000-00001     Document Type: Article

References (46)

1. Slingluff CL Jr. Tumor antigens and tumor vaccines: peptides as immunogens. Semin Surg Oncol 1996;12:446-53.
2. Alieva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-a production. J Immunol 1994;153:1674-86.
3. Roberts AB, Spom MB. The transforming growth factor-ps. In: Spom MB, Roberts AB, eds. Peptide growth factors and their receptors. Berlin: Springer-Verlag, 1990:419-72. (Handbook of experimental pharmacology; vol 95).
4. Walker RA, Dearing SJ, Gallacher B. Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 1994;69:1160-5.
5. McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB. Localization of transforming growth factor-P isotypes in lesions of the human breast. Hum Pathol 1992;23:13-20.
6. Mizukami Y, Nonomura A, Yamada T, et al. Immunohistochemical demonstration of growth factors, TGF-a, TGF-P, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res 1990;10:1115-26.
7. Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987;48:417-28.
8. King RJB, Wang DY, Daly RJ, Darbre PD. Approaches to studying the role of growth factors in the progression of breast tumors from the steroid sensitive to insensitive state. J Steroid Biochem 1989;34:133-8.
9. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor pi associates with disease progression in human breast cancer. Cancer Res 1992;52:6949-52.
10. MacCallum J, Bartlett JMS, Thompson AM, Keen JC, Dixon JM, Millef WR. Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer 1994;69:1006-9.
11. Arteaga CL, Dugger TC, Winnier AR, Forbes JT. Evidence for a positive role of transforming growth factor-P in human breast cancer cell tumorigenesis. J Cell Biochem 1993;17:187-93.
12. Ortaldo JR, Mason AT, O’Shea JJ, et al. Mechanistic studies of transforming growth factor-P inhibition of IL-2-dependent activation of CD3-large granular lymphocyte functions. J Immunol 1991;146:3791-8.
13. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA. Immunoregulatory role of transforming growth factor-β in development of killer cells: comparison of active and latent TGF-β 1. J Exp Med 1990;172:1777-84.
14. Espevik T, Figari IS, Ranges GE, Palladino MA Jr. Transforming growth factor-β 1 (TGFβ-1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokineactivated killer cell activity. J Immunol 1988;140:2312-6.
15. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136:3916-20.
16. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors. J Immunol 1988;141:690-8.
17. Jin B, Scott JL, Vadas MA, Bums GF. TGFp down-regulates TLiSAl expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 1989;66:570-6.
18. Mule JJ, Schwarz SL, Roberts AB, Spom MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988;26:95-100.
19. 2-macroglobulins. Lab Invest 1991;65:3-14.
20. Sottrup-Jensen L. α-Macroglobulins: structure, shape and mechanisms of proteinase complex formation. J Biol Chem 1989;264:11539-42.
21. 2-macroglobulin following a reaction with methylamine and trypsin. Biochem Biophys Acta 1982;705:306-14.
22. Crookston K, Webb DJ, Wolf BB, Gonias SL. Classification of α-macroglobulin-cytokine interactions based on affinity of non-covalent dissociation in solution under apparent equilibrium conditions. J Biol Chem 1994;269:1533-40.
23. Phillip A, O’Connor-McCourt MD. Interaction of transforming growth factor-β1 with α-macroglobulin. Role in transforming growth factor-α1 clearance. J Biol Chem 1991;266:2290-6.
24. LaMarre J, Hayes MA, Wollenberg GK, Hussaini I, Hall SW, Gonias SL. An α-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-p 1 in mice. J Clin Invest 1991;87:39-14.
25. Burmester JK, Quian SW, Roberts AB, et al. Characterization of distinct functional domains of transforming growth factor-β. Proc Natl Acad Sci USA 1993;90:8628-32.
26. 2-macroglobulin increase expression of platelet-derived growth factor α-receptor in vascular smooth muscle cells. J Biol Chem 1995;270:30741-8.
27. 2-Macroglobulin functions as a cytokine carrier to induce nitric oxide synthesis and cause nitric oxide-dependent cytotoxicity in the RAW 264.7 macrophage cell line. J Biol Chem 1995;270:21919-27.
28. Imber MJ, Pizzo SV. Clearance and binding of two electrophoretic “fast” forms of human alpha 2-macroglobulin. J Biol Chem 1981;256:8134-9.
29. Slingluff CL Jr, Cox AL, Henderson RA, Hunt DF, Engelhard VH. Recognition of human melanoma cells by HLA-A2.1restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol 1993;150:2955-63.
30. Spom MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-α: biological function and chemical structure. Science 1986;233:532-4.
31. Nunes I, Munger JS, Harpel JG, et al. Structure and activation of the large latent transforming growth factor-α complex. Int J Obesity Rel Metab Dis 1996;20(suppl 3):S4-8.
32. Yannelli JR, Hyatt C, McConnell S, et al. Growth of tumorinfiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 1996;65:413-21.
33. Cotran RS, Kumar V, Robbins SL. Neoplasia. In: Cotran RS, Kumar V, Robbins SL, eds. Pathologic basis of disease. 4th ed. Philadelphia: Mosby, 1989:297.
34. Bonilla F, Alvarez-Mon M, Merino F, et al. Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer 1988;61:629-34.
35. Cochran AJ, Pihl E, Wen DR, Hoon DS, Korn EL. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. JNCI 1987;78:399-405.
36. Hersey P, Si Z, Smith MJ, Thomas WD. Expression of the costimulatory molecule B7 on melanoma cells. Int J Cancer 1994;58:527-32.
37. Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993;11:165-90.
38. 2-macroglobulin gene. J Biol Chem 1995;270:19778-85.
39. 2-macroglobulin. J Biol Chem 1995;270:8381-4.
40. Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature 1988;332:217-9.
41. Mule JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 1985;135:646-52.
42. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
43. Rosenberg SA, Yannelli JR, Yang JC. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. JNCI 1994;86:1159-66.
44. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
45. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. JNCI 1993;85:622-32.
46. Sparano JA, Fisher RI, Weiss GR, et al. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors. J Immunother 1994;16:216-23.